Antipsychotic treatment and extrapyramidal symptoms amongst schizophrenic inpatients

Nordic Journal of Psychiatry

Volumn 60, Issue 3, 2006, Pages 207-212

  Hoiberg M P ^a   Nielsen, Bent ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

EPS; Re hospitalization; Schizophrenic inpatients

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT;

ADULT; AKATHISIA; AKINESIA; ANALYSIS OF VARIANCE; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FUNCTIONAL ASSESSMENT; HOSPITAL PATIENT; HOSPITAL READMISSION; HUMAN; HYPERKINESIA; HYPOKINESIA; INCIDENCE; INTERNATIONAL CLASSIFICATION OF DISEASES; LENGTH OF STAY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MUSCLE RIGIDITY; NEGATIVE SYNDROME; PARESTHESIA; PARKINSONISM; POSITIVE SYNDROME; PSYCHOLOGICAL RATING SCALE; RISK ASSESSMENT; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; TREMOR;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOSPITALIZATION; HOSPITALS, PSYCHIATRIC; HUMANS; MALE; QUALITY ASSURANCE, HEALTH CARE; SCHIZOPHRENIA; TIME FACTORS; TREATMENT FAILURE;

EID: 33744818932     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.1080/08039480600636296     Document Type: Article

References (18)

1. Kopala, LC. (1996) Spontaneous and drug-induced movement disorders in schizophrenia Acta Psychiatr Scand, 94, pp. 12-7.
2. Casey, DE. (1997) The relationship of pharmacology to side effects J Clin Psychiatry, 58 Suppl 10, pp. 55-62.
3. Keks, NA. (1996) Minimizing the non-extrapyramidal side-effects of antipsychotics Acta Psychiatr Scand, 94, pp. 18-24.
4. Schultz, CS. (2000) New antipsychotic medications: More than old wine and new bottles Bull Menninger Clin, 64, pp. 60-75.
5. Kane, John. (1999) Olanzapine in the long-term treatment of schizophrenia Br J Psychiatry, 174 Suppl 37, pp. 26-9.
6. Tollefson, GD and Beasley, CM, Jr and Tran, PV and Street, JS. (1997) Olanzapine vs. haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial Am J Psychiatry, 154, pp. 457-65.
7. Valenstein, M and Copeland, LA and Blow, FC and McCarthy, JF and Zeber, JE and Gillon, L and (2002) Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission Med Care, 40, pp. 630-9.
8. Leucht, S and Pitschel-Walz, G and Abraham, D and Kissling, W. (1999) Efficacy and extra pyramidal side-effect of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials Schizophr Res, 35, pp. 51-68.
9. Peuskens, J. (1998) Good medical practice in antipsychotic pharmacotherapy Int Clin Psychopharmacol, 13 Suppl 3, pp. 535-41.
10. Gilbody, S and Wahlbeck, K and Adams, C. (2002) Randomized controlled trials in schizophrenia: A critical perspective of the literature Acta Psychiatr Scand, 105, pp. 243-51.
11. Beck, P and Kastrup, M and Rafaelsen, OJ. (1986) Mini-compendium of rating scales for states of anxiety, depression, mania, schizophrenia with corresponding DSM-III syndromes Acta Psychiatr Scand;76 Suppl, 326, pp. 32-7.
12. Nicholson, IR and Chapman, JE and Neufeld, RWJ. (1995) Variability in BPRS definitions of positive and negative symptoms Schizophr Res, 17, pp. 177-85.
13. OhlsenR, SmithS, TaylorD, PilowskyL. The UKU Side-effect Rating Scale. In: OhlsenR, SmithS, TaylorD, PilowskyL. Antipsychotic medication review - Service guidelines. Sanders: Editor Martin Dunitz; 2003.
14. Sharpiro, S. (1997) Confounding by indication Epidemiology, 8, pp. 110.
15. Hamilton, SH and Revicki, DA and Edgell, ET and Genduso, LA and Tollefson, G. (1999) Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: Results from a randomised clinical trial Pharmacoeconomics, 15, pp. 469-80.
16. Wahlbeck, K and Tuunainen, A and Ahokas, A and Leucht, S. (2001) Dropout rates in randomised antipsychotic drug trials Psychopharmacology, 155, pp. 230-3.
17. Chakos, MH and Alvir, JM and Woerner, MG and Koreen, A and Geisler, S and Mayerhoff, D and (1996) Incidence and correlates of tardive dyskinesia in first episode of schizophrenia Arch Gen Psychiatry, 53, pp. 313-9.
18. Esseck, MS and Drake, ER and Frank, GR and McQuire, GT. (2003) Randomized controlled trials in evidence-based mental health care: Getting the right answer to the right question Schizophr Bul, 29, pp. 115-23.